Augmentation of aripiprazole with low-dose clozapine

Pharmacotherapy

Volumn 27, Issue 11, 2007, Pages 1599-1602

  Stoner, Steven C ^a,b   Dahmen, Megan M ^a,b   Berges, Arnaldo ^b   Petry, Whitney M ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b Northwest Missouri Psychiatric Rehabilitation Center   (United States)

Author keywords

Aripiprazole; Augmentation; Clozapine; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLONAZEPAM; CLOZAPINE; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; RISPERIDONE; TRAZODONE;

ADULT; ARTICLE; CASE REPORT; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG WITHDRAWAL; HUMAN; INSOMNIA; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; MONOTHERAPY; PARANOID SCHIZOPHRENIA; PATIENT COMPLIANCE; SEDATION; SIDE EFFECT; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; MALE; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA, PARANOID; SLEEP; TREATMENT OUTCOME;

EID: 35848964070     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.11.1599     Document Type: Article

References (28)

1. Bristol-Myers Squibb. Abilify (aripiprazole) package insert. Princeton, NJ; 2006.
2. 2 receptor antagonistic activity. J Pharmacol Exp Ther 1995;274:329-36.
3. Novartis Pharmaceuticals. Clozaril (clozapine) package insert. East Hanover, NJ; 2005.
4. Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994;55(suppl B):47-52.
5. Lieberman JA. Maximizing clozapine therapy: managing side effects. J Clin Psychiatry 1998;59(suppl 3):38-43.
6. VanderZwaag C, McGee M, McEvoy JP, et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996; 153:1579-84.
7. Ulrich S, Baumann B, Wolf R, et al. Therapeutic drug monitoring of clozapine and relapse: a retrospective study of routine clinical data. Int J Clin Pharmacol Ther 2003; 41(1):3-13.
8. Schulte PFJ. What is an adequate trial with clozapine? Clin Pharmacokinet 2003;42(7):607-18.
9. 2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001;158(3):360-9.
10. Wang PS, West JC, Tanielian T, Pincus HA. Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr Bull 2000;26:451-7.
11. Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry 1999;60(suppl 10):20-30.
12. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 2004;161(2):1-58.
13. Honer WG, Thornton AE, Chen EYH, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006;354:472-82.
14. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005;162:130-6.
15. Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004;161:700-6.
16. Stahl SM, Grady MM. High-cost use of second-generation antipsychotics under California's Medicaid program. Psychiatr Serv 2006;57(1):127-9.
17. Abu-Tair F, Kopitz J, Bergemann N. Clozapine augmented with aripiprazole in 5 patients with schizophrenia. J Clin Psychopharmacol 2006;26(6):669-71.
18. Clarke LA. Clozapine augmentation with aripiprazole for negative symptoms. J Clin Psychiatry 2006;67(4):675-6.
19. Ziegenbein M, Sieberer M, Calliess IT, Kropp S. Combination of clozapine and aripiprazole: a promising approach in treatment-resistant schizophrenia. Aust N Z J Psychiatry 2005;39(9):840-1.
20. Lim S, Pralea C, Schnitt J, Bowers MB, Cooper C. Possible increased efficacy of low-dose clozapine when combined with aripiprazole. J Clin Psychiatry 2004;65(9):1284-5.
21. DeQuardo JR. Increased efficacy with addition of clozapine to aripiprazole: alternative explanations [letter]. J Clin Psych 2005;66(3):396.
22. Friedman JI. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology 2004;174:45-53.
23. 1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 2004;174:3-16.
24. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004;9:984-97.
25. Tamminga CA. The neurobiology of cognition in schizophrenia. J Clin Psychiatry 2006;67(suppl 9):9-13.
26. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of the alpha-7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006;63:630-8.
27. Carlsson ML, Carlsson A, Nilsson M. Schizophrenia: from dopamine to glutamate and back. Curr Med Chem 2004;11: 267-77.
28. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999;60(suppl 10):5-14.